Tuesday, March 11, 2025
HomeMarketing AnalyticsAlembic Pharmaceuticals announces USFDA Final Approval for Alcaftadine Ophthalmic Solution, 0.25% (OTC)

Alembic Pharmaceuticals announces USFDA Final Approval for Alcaftadine Ophthalmic Solution, 0.25% (OTC)

4th October 2024, Bengaluru: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Alcaftadine Ophthalmic Solution, 0.25% (OTC).

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Lastacaft Solution, 0.25%, of AbbVie Inc. (AbbVie). Alcaftadine Ophthalmic Solution, 0.25% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander. Refer label for a detailed indication.

Alembic has a cumulative total of 216 ANDA approvals (189 final approvals and 27 tentative approvals) from USFDA.

 

Passionate in Marketing
Passionate in Marketinghttp://www.passionateinmarketing.com
Passionate in Marketing, one of the biggest publishing platforms in India invites industry professionals and academicians to share your thoughts and views on latest marketing trends by contributing articles and get yourself heard.
Read More
- Advertisment -

Latest Posts